nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—Embolism venous—Sorafenib—liver cancer	0.0261	0.0283	CcSEcCtD
Lurasidone—Suicide—Sorafenib—liver cancer	0.0254	0.0275	CcSEcCtD
Lurasidone—Completed suicide—Sorafenib—liver cancer	0.0224	0.0242	CcSEcCtD
Lurasidone—Venous thromboembolism—Epirubicin—liver cancer	0.0165	0.0179	CcSEcCtD
Lurasidone—Venous thromboembolism—Doxorubicin—liver cancer	0.0153	0.0166	CcSEcCtD
Lurasidone—Rhabdomyolysis—Sorafenib—liver cancer	0.0149	0.0161	CcSEcCtD
Lurasidone—Blood pressure increased—Sorafenib—liver cancer	0.0132	0.0143	CcSEcCtD
Lurasidone—Embolism venous—Epirubicin—liver cancer	0.00963	0.0104	CcSEcCtD
Lurasidone—Embolism venous—Doxorubicin—liver cancer	0.00891	0.00966	CcSEcCtD
Lurasidone—Abdominal pain upper—Sorafenib—liver cancer	0.00872	0.00945	CcSEcCtD
Lurasidone—Breast disorder—Sorafenib—liver cancer	0.00863	0.00935	CcSEcCtD
Lurasidone—Nasopharyngitis—Sorafenib—liver cancer	0.00854	0.00926	CcSEcCtD
Lurasidone—Gastritis—Sorafenib—liver cancer	0.00845	0.00916	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Sorafenib—liver cancer	0.00842	0.00913	CcSEcCtD
Lurasidone—Dysphagia—Sorafenib—liver cancer	0.00825	0.00895	CcSEcCtD
Lurasidone—Abdominal discomfort—Sorafenib—liver cancer	0.00791	0.00858	CcSEcCtD
Lurasidone—Serum creatinine increased—Epirubicin—liver cancer	0.0079	0.00857	CcSEcCtD
Lurasidone—Neutropenia—Sorafenib—liver cancer	0.00772	0.00837	CcSEcCtD
Lurasidone—Erectile dysfunction—Sorafenib—liver cancer	0.0076	0.00824	CcSEcCtD
Lurasidone—Infestation NOS—Sorafenib—liver cancer	0.00736	0.00798	CcSEcCtD
Lurasidone—Infestation—Sorafenib—liver cancer	0.00736	0.00798	CcSEcCtD
Lurasidone—Serum creatinine increased—Doxorubicin—liver cancer	0.00731	0.00793	CcSEcCtD
Lurasidone—Renal failure—Sorafenib—liver cancer	0.00723	0.00784	CcSEcCtD
Lurasidone—Hypokinesia—Epirubicin—liver cancer	0.0072	0.00781	CcSEcCtD
Lurasidone—Hepatobiliary disease—Sorafenib—liver cancer	0.00696	0.00754	CcSEcCtD
Lurasidone—Hypokinesia—Doxorubicin—liver cancer	0.00666	0.00722	CcSEcCtD
Lurasidone—Urinary tract disorder—Sorafenib—liver cancer	0.00652	0.00707	CcSEcCtD
Lurasidone—Connective tissue disorder—Sorafenib—liver cancer	0.00649	0.00704	CcSEcCtD
Lurasidone—Urethral disorder—Sorafenib—liver cancer	0.00647	0.00702	CcSEcCtD
Lurasidone—Cardiac disorder—Sorafenib—liver cancer	0.00613	0.00665	CcSEcCtD
Lurasidone—Angiopathy—Sorafenib—liver cancer	0.00599	0.0065	CcSEcCtD
Lurasidone—Arrhythmia—Sorafenib—liver cancer	0.0059	0.0064	CcSEcCtD
Lurasidone—Mental disorder—Sorafenib—liver cancer	0.00579	0.00627	CcSEcCtD
Lurasidone—Malnutrition—Sorafenib—liver cancer	0.00575	0.00623	CcSEcCtD
Lurasidone—Breast pain—Epirubicin—liver cancer	0.00557	0.00604	CcSEcCtD
Lurasidone—Cardiovascular disorder—Epirubicin—liver cancer	0.00553	0.006	CcSEcCtD
Lurasidone—Amenorrhoea—Epirubicin—liver cancer	0.00553	0.006	CcSEcCtD
Lurasidone—Muscle spasms—Sorafenib—liver cancer	0.00553	0.00599	CcSEcCtD
Lurasidone—Anaemia—Sorafenib—liver cancer	0.00531	0.00576	CcSEcCtD
Lurasidone—Angioedema—Sorafenib—liver cancer	0.00525	0.0057	CcSEcCtD
Lurasidone—Dyskinesia—Epirubicin—liver cancer	0.00517	0.00561	CcSEcCtD
Lurasidone—Syncope—Sorafenib—liver cancer	0.00516	0.00559	CcSEcCtD
Lurasidone—Breast pain—Doxorubicin—liver cancer	0.00515	0.00559	CcSEcCtD
Lurasidone—Leukopenia—Sorafenib—liver cancer	0.00515	0.00558	CcSEcCtD
Lurasidone—Dysarthria—Epirubicin—liver cancer	0.00514	0.00557	CcSEcCtD
Lurasidone—Amenorrhoea—Doxorubicin—liver cancer	0.00512	0.00555	CcSEcCtD
Lurasidone—Cardiovascular disorder—Doxorubicin—liver cancer	0.00512	0.00555	CcSEcCtD
Lurasidone—Creatinine increased—Epirubicin—liver cancer	0.00511	0.00554	CcSEcCtD
Lurasidone—Loss of consciousness—Sorafenib—liver cancer	0.00505	0.00548	CcSEcCtD
Lurasidone—Atrioventricular block—Epirubicin—liver cancer	0.00501	0.00543	CcSEcCtD
Lurasidone—Gait disturbance—Epirubicin—liver cancer	0.00498	0.0054	CcSEcCtD
Lurasidone—Hypertension—Sorafenib—liver cancer	0.00496	0.00538	CcSEcCtD
Lurasidone—Neck pain—Epirubicin—liver cancer	0.00492	0.00533	CcSEcCtD
Lurasidone—Myalgia—Sorafenib—liver cancer	0.00489	0.00531	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00486	0.00527	CcSEcCtD
Lurasidone—Pulmonary embolism—Epirubicin—liver cancer	0.00486	0.00527	CcSEcCtD
Lurasidone—Abnormal dreams—Epirubicin—liver cancer	0.0048	0.00521	CcSEcCtD
Lurasidone—Dry mouth—Sorafenib—liver cancer	0.00479	0.00519	CcSEcCtD
Lurasidone—Dyskinesia—Doxorubicin—liver cancer	0.00479	0.00519	CcSEcCtD
Lurasidone—Dysarthria—Doxorubicin—liver cancer	0.00475	0.00515	CcSEcCtD
Lurasidone—Creatinine increased—Doxorubicin—liver cancer	0.00472	0.00512	CcSEcCtD
Lurasidone—Salivary hypersecretion—Epirubicin—liver cancer	0.00472	0.00512	CcSEcCtD
Lurasidone—Infection—Sorafenib—liver cancer	0.00466	0.00505	CcSEcCtD
Lurasidone—Atrioventricular block—Doxorubicin—liver cancer	0.00464	0.00503	CcSEcCtD
Lurasidone—Shock—Sorafenib—liver cancer	0.00462	0.005	CcSEcCtD
Lurasidone—Gait disturbance—Doxorubicin—liver cancer	0.00461	0.005	CcSEcCtD
Lurasidone—Nervous system disorder—Sorafenib—liver cancer	0.0046	0.00499	CcSEcCtD
Lurasidone—Skin disorder—Sorafenib—liver cancer	0.00456	0.00494	CcSEcCtD
Lurasidone—Neck pain—Doxorubicin—liver cancer	0.00455	0.00494	CcSEcCtD
Lurasidone—Pulmonary embolism—Doxorubicin—liver cancer	0.0045	0.00488	CcSEcCtD
Lurasidone—Abnormal dreams—Doxorubicin—liver cancer	0.00444	0.00482	CcSEcCtD
Lurasidone—Salivary hypersecretion—Doxorubicin—liver cancer	0.00437	0.00474	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00427	0.00463	CcSEcCtD
Lurasidone—Dyspnoea—Sorafenib—liver cancer	0.00418	0.00454	CcSEcCtD
Lurasidone—Dyspepsia—Sorafenib—liver cancer	0.00413	0.00448	CcSEcCtD
Lurasidone—Decreased appetite—Sorafenib—liver cancer	0.00408	0.00442	CcSEcCtD
Lurasidone—Diabetes mellitus—Epirubicin—liver cancer	0.00406	0.0044	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Sorafenib—liver cancer	0.00405	0.00439	CcSEcCtD
Lurasidone—Fatigue—Sorafenib—liver cancer	0.00405	0.00439	CcSEcCtD
Lurasidone—Gastrointestinal pain—Sorafenib—liver cancer	0.00384	0.00416	CcSEcCtD
Lurasidone—Hot flush—Epirubicin—liver cancer	0.00377	0.00409	CcSEcCtD
Lurasidone—Increased appetite—Epirubicin—liver cancer	0.00376	0.00407	CcSEcCtD
Lurasidone—Diabetes mellitus—Doxorubicin—liver cancer	0.00375	0.00407	CcSEcCtD
Lurasidone—Menopausal symptoms—Epirubicin—liver cancer	0.00374	0.00405	CcSEcCtD
Lurasidone—Abdominal pain—Sorafenib—liver cancer	0.00371	0.00402	CcSEcCtD
Lurasidone—Cerebrovascular accident—Epirubicin—liver cancer	0.0036	0.0039	CcSEcCtD
Lurasidone—Lethargy—Epirubicin—liver cancer	0.0036	0.0039	CcSEcCtD
Lurasidone—Osteoarthritis—Epirubicin—liver cancer	0.00353	0.00383	CcSEcCtD
Lurasidone—Hot flush—Doxorubicin—liver cancer	0.00349	0.00378	CcSEcCtD
Lurasidone—Increased appetite—Doxorubicin—liver cancer	0.00347	0.00377	CcSEcCtD
Lurasidone—Menopausal symptoms—Doxorubicin—liver cancer	0.00346	0.00375	CcSEcCtD
Lurasidone—Asthenia—Sorafenib—liver cancer	0.00337	0.00365	CcSEcCtD
Lurasidone—Cerebrovascular accident—Doxorubicin—liver cancer	0.00333	0.00361	CcSEcCtD
Lurasidone—Lethargy—Doxorubicin—liver cancer	0.00333	0.00361	CcSEcCtD
Lurasidone—Pruritus—Sorafenib—liver cancer	0.00332	0.0036	CcSEcCtD
Lurasidone—Blood creatinine increased—Epirubicin—liver cancer	0.00331	0.00358	CcSEcCtD
Lurasidone—Osteoarthritis—Doxorubicin—liver cancer	0.00326	0.00354	CcSEcCtD
Lurasidone—Orthostatic hypotension—Epirubicin—liver cancer	0.00322	0.00349	CcSEcCtD
Lurasidone—Abdominal pain upper—Epirubicin—liver cancer	0.00322	0.00349	CcSEcCtD
Lurasidone—Diarrhoea—Sorafenib—liver cancer	0.00321	0.00348	CcSEcCtD
Lurasidone—Breast disorder—Epirubicin—liver cancer	0.00319	0.00346	CcSEcCtD
Lurasidone—Nasopharyngitis—Epirubicin—liver cancer	0.00315	0.00342	CcSEcCtD
Lurasidone—Gastritis—Epirubicin—liver cancer	0.00312	0.00339	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00311	0.00337	CcSEcCtD
Lurasidone—Dizziness—Sorafenib—liver cancer	0.0031	0.00336	CcSEcCtD
Lurasidone—Blood creatinine increased—Doxorubicin—liver cancer	0.00306	0.00332	CcSEcCtD
Lurasidone—Influenza—Epirubicin—liver cancer	0.00305	0.00331	CcSEcCtD
Lurasidone—Dysphagia—Epirubicin—liver cancer	0.00305	0.00331	CcSEcCtD
Lurasidone—Eosinophilia—Epirubicin—liver cancer	0.00302	0.00327	CcSEcCtD
Lurasidone—Vomiting—Sorafenib—liver cancer	0.00298	0.00323	CcSEcCtD
Lurasidone—Orthostatic hypotension—Doxorubicin—liver cancer	0.00298	0.00323	CcSEcCtD
Lurasidone—Abdominal pain upper—Doxorubicin—liver cancer	0.00298	0.00323	CcSEcCtD
Lurasidone—Angina pectoris—Epirubicin—liver cancer	0.00297	0.00322	CcSEcCtD
Lurasidone—Rash—Sorafenib—liver cancer	0.00296	0.00321	CcSEcCtD
Lurasidone—Dermatitis—Sorafenib—liver cancer	0.00296	0.0032	CcSEcCtD
Lurasidone—Breast disorder—Doxorubicin—liver cancer	0.00295	0.0032	CcSEcCtD
Lurasidone—Nasopharyngitis—Doxorubicin—liver cancer	0.00292	0.00316	CcSEcCtD
Lurasidone—Gastritis—Doxorubicin—liver cancer	0.00289	0.00313	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.00288	0.00312	CcSEcCtD
Lurasidone—Dysuria—Epirubicin—liver cancer	0.00285	0.00309	CcSEcCtD
Lurasidone—Neutropenia—Epirubicin—liver cancer	0.00285	0.00309	CcSEcCtD
Lurasidone—Dysphagia—Doxorubicin—liver cancer	0.00282	0.00306	CcSEcCtD
Lurasidone—Influenza—Doxorubicin—liver cancer	0.00282	0.00306	CcSEcCtD
Lurasidone—Eosinophilia—Doxorubicin—liver cancer	0.00279	0.00303	CcSEcCtD
Lurasidone—Nausea—Sorafenib—liver cancer	0.00279	0.00302	CcSEcCtD
Lurasidone—Weight increased—Epirubicin—liver cancer	0.00278	0.00301	CcSEcCtD
Lurasidone—Hyperglycaemia—Epirubicin—liver cancer	0.00275	0.00298	CcSEcCtD
Lurasidone—Angina pectoris—Doxorubicin—liver cancer	0.00275	0.00298	CcSEcCtD
Lurasidone—Infestation NOS—Epirubicin—liver cancer	0.00272	0.00295	CcSEcCtD
Lurasidone—Infestation—Epirubicin—liver cancer	0.00272	0.00295	CcSEcCtD
Lurasidone—Renal failure—Epirubicin—liver cancer	0.00267	0.0029	CcSEcCtD
Lurasidone—Urinary tract infection—Epirubicin—liver cancer	0.00264	0.00287	CcSEcCtD
Lurasidone—Dysuria—Doxorubicin—liver cancer	0.00264	0.00286	CcSEcCtD
Lurasidone—Neutropenia—Doxorubicin—liver cancer	0.00264	0.00286	CcSEcCtD
Lurasidone—Hepatobiliary disease—Epirubicin—liver cancer	0.00257	0.00279	CcSEcCtD
Lurasidone—Weight increased—Doxorubicin—liver cancer	0.00257	0.00278	CcSEcCtD
Lurasidone—Hyperglycaemia—Doxorubicin—liver cancer	0.00255	0.00276	CcSEcCtD
Lurasidone—Agranulocytosis—Epirubicin—liver cancer	0.00254	0.00275	CcSEcCtD
Lurasidone—Infestation NOS—Doxorubicin—liver cancer	0.00252	0.00273	CcSEcCtD
Lurasidone—Infestation—Doxorubicin—liver cancer	0.00252	0.00273	CcSEcCtD
Lurasidone—Bradycardia—Epirubicin—liver cancer	0.00248	0.00269	CcSEcCtD
Lurasidone—Renal failure—Doxorubicin—liver cancer	0.00247	0.00268	CcSEcCtD
Lurasidone—Urinary tract infection—Doxorubicin—liver cancer	0.00245	0.00265	CcSEcCtD
Lurasidone—Urinary tract disorder—Epirubicin—liver cancer	0.00241	0.00261	CcSEcCtD
Lurasidone—Connective tissue disorder—Epirubicin—liver cancer	0.0024	0.0026	CcSEcCtD
Lurasidone—Urethral disorder—Epirubicin—liver cancer	0.00239	0.00259	CcSEcCtD
Lurasidone—Hepatobiliary disease—Doxorubicin—liver cancer	0.00238	0.00258	CcSEcCtD
Lurasidone—Agranulocytosis—Doxorubicin—liver cancer	0.00235	0.00255	CcSEcCtD
Lurasidone—Bradycardia—Doxorubicin—liver cancer	0.0023	0.00249	CcSEcCtD
Lurasidone—Eye disorder—Epirubicin—liver cancer	0.00228	0.00247	CcSEcCtD
Lurasidone—Cardiac disorder—Epirubicin—liver cancer	0.00227	0.00246	CcSEcCtD
Lurasidone—Urinary tract disorder—Doxorubicin—liver cancer	0.00223	0.00242	CcSEcCtD
Lurasidone—Connective tissue disorder—Doxorubicin—liver cancer	0.00222	0.00241	CcSEcCtD
Lurasidone—Angiopathy—Epirubicin—liver cancer	0.00221	0.0024	CcSEcCtD
Lurasidone—Urethral disorder—Doxorubicin—liver cancer	0.00221	0.0024	CcSEcCtD
Lurasidone—Arrhythmia—Epirubicin—liver cancer	0.00218	0.00236	CcSEcCtD
Lurasidone—Mental disorder—Epirubicin—liver cancer	0.00214	0.00232	CcSEcCtD
Lurasidone—Malnutrition—Epirubicin—liver cancer	0.00212	0.0023	CcSEcCtD
Lurasidone—Eye disorder—Doxorubicin—liver cancer	0.00211	0.00229	CcSEcCtD
Lurasidone—Cardiac disorder—Doxorubicin—liver cancer	0.0021	0.00227	CcSEcCtD
Lurasidone—Flatulence—Epirubicin—liver cancer	0.00209	0.00227	CcSEcCtD
Lurasidone—Back pain—Epirubicin—liver cancer	0.00206	0.00223	CcSEcCtD
Lurasidone—Angiopathy—Doxorubicin—liver cancer	0.00205	0.00222	CcSEcCtD
Lurasidone—Muscle spasms—Epirubicin—liver cancer	0.00204	0.00221	CcSEcCtD
Lurasidone—Arrhythmia—Doxorubicin—liver cancer	0.00202	0.00219	CcSEcCtD
Lurasidone—Vision blurred—Epirubicin—liver cancer	0.002	0.00217	CcSEcCtD
Lurasidone—Mental disorder—Doxorubicin—liver cancer	0.00198	0.00215	CcSEcCtD
Lurasidone—Malnutrition—Doxorubicin—liver cancer	0.00197	0.00213	CcSEcCtD
Lurasidone—Anaemia—Epirubicin—liver cancer	0.00196	0.00213	CcSEcCtD
Lurasidone—Agitation—Epirubicin—liver cancer	0.00195	0.00212	CcSEcCtD
Lurasidone—Flatulence—Doxorubicin—liver cancer	0.00194	0.0021	CcSEcCtD
Lurasidone—Malaise—Epirubicin—liver cancer	0.00192	0.00208	CcSEcCtD
Lurasidone—Vertigo—Epirubicin—liver cancer	0.00191	0.00207	CcSEcCtD
Lurasidone—Syncope—Epirubicin—liver cancer	0.00191	0.00207	CcSEcCtD
Lurasidone—Leukopenia—Epirubicin—liver cancer	0.0019	0.00206	CcSEcCtD
Lurasidone—Back pain—Doxorubicin—liver cancer	0.0019	0.00206	CcSEcCtD
Lurasidone—Muscle spasms—Doxorubicin—liver cancer	0.00189	0.00205	CcSEcCtD
Lurasidone—Loss of consciousness—Epirubicin—liver cancer	0.00187	0.00202	CcSEcCtD
Lurasidone—Vision blurred—Doxorubicin—liver cancer	0.00185	0.00201	CcSEcCtD
Lurasidone—Convulsion—Epirubicin—liver cancer	0.00184	0.002	CcSEcCtD
Lurasidone—Hypertension—Epirubicin—liver cancer	0.00183	0.00199	CcSEcCtD
Lurasidone—Anaemia—Doxorubicin—liver cancer	0.00182	0.00197	CcSEcCtD
Lurasidone—Myalgia—Epirubicin—liver cancer	0.00181	0.00196	CcSEcCtD
Lurasidone—Agitation—Doxorubicin—liver cancer	0.00181	0.00196	CcSEcCtD
Lurasidone—Anxiety—Epirubicin—liver cancer	0.0018	0.00195	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.0018	0.00195	CcSEcCtD
Lurasidone—Malaise—Doxorubicin—liver cancer	0.00177	0.00192	CcSEcCtD
Lurasidone—Dry mouth—Epirubicin—liver cancer	0.00177	0.00192	CcSEcCtD
Lurasidone—Vertigo—Doxorubicin—liver cancer	0.00177	0.00192	CcSEcCtD
Lurasidone—Syncope—Doxorubicin—liver cancer	0.00176	0.00191	CcSEcCtD
Lurasidone—Leukopenia—Doxorubicin—liver cancer	0.00176	0.00191	CcSEcCtD
Lurasidone—Loss of consciousness—Doxorubicin—liver cancer	0.00173	0.00187	CcSEcCtD
Lurasidone—Infection—Epirubicin—liver cancer	0.00172	0.00187	CcSEcCtD
Lurasidone—Shock—Epirubicin—liver cancer	0.00171	0.00185	CcSEcCtD
Lurasidone—Convulsion—Doxorubicin—liver cancer	0.0017	0.00185	CcSEcCtD
Lurasidone—Nervous system disorder—Epirubicin—liver cancer	0.0017	0.00184	CcSEcCtD
Lurasidone—Hypertension—Doxorubicin—liver cancer	0.0017	0.00184	CcSEcCtD
Lurasidone—Tachycardia—Epirubicin—liver cancer	0.00169	0.00183	CcSEcCtD
Lurasidone—Skin disorder—Epirubicin—liver cancer	0.00168	0.00183	CcSEcCtD
Lurasidone—Hyperhidrosis—Epirubicin—liver cancer	0.00168	0.00182	CcSEcCtD
Lurasidone—Myalgia—Doxorubicin—liver cancer	0.00167	0.00181	CcSEcCtD
Lurasidone—Anxiety—Doxorubicin—liver cancer	0.00167	0.00181	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00166	0.0018	CcSEcCtD
Lurasidone—Dry mouth—Doxorubicin—liver cancer	0.00164	0.00177	CcSEcCtD
Lurasidone—Hypotension—Epirubicin—liver cancer	0.00162	0.00176	CcSEcCtD
Lurasidone—Infection—Doxorubicin—liver cancer	0.00159	0.00173	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00158	0.00171	CcSEcCtD
Lurasidone—Shock—Doxorubicin—liver cancer	0.00158	0.00171	CcSEcCtD
Lurasidone—Nervous system disorder—Doxorubicin—liver cancer	0.00157	0.00171	CcSEcCtD
Lurasidone—Insomnia—Epirubicin—liver cancer	0.00157	0.0017	CcSEcCtD
Lurasidone—Tachycardia—Doxorubicin—liver cancer	0.00157	0.0017	CcSEcCtD
Lurasidone—Skin disorder—Doxorubicin—liver cancer	0.00156	0.00169	CcSEcCtD
Lurasidone—Hyperhidrosis—Doxorubicin—liver cancer	0.00155	0.00168	CcSEcCtD
Lurasidone—Dyspnoea—Epirubicin—liver cancer	0.00155	0.00168	CcSEcCtD
Lurasidone—Somnolence—Epirubicin—liver cancer	0.00154	0.00167	CcSEcCtD
Lurasidone—Dyspepsia—Epirubicin—liver cancer	0.00153	0.00165	CcSEcCtD
Lurasidone—Decreased appetite—Epirubicin—liver cancer	0.00151	0.00163	CcSEcCtD
Lurasidone—Hypotension—Doxorubicin—liver cancer	0.0015	0.00163	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Epirubicin—liver cancer	0.0015	0.00162	CcSEcCtD
Lurasidone—Fatigue—Epirubicin—liver cancer	0.0015	0.00162	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00146	0.00158	CcSEcCtD
Lurasidone—Insomnia—Doxorubicin—liver cancer	0.00145	0.00157	CcSEcCtD
Lurasidone—Dyspnoea—Doxorubicin—liver cancer	0.00143	0.00155	CcSEcCtD
Lurasidone—Somnolence—Doxorubicin—liver cancer	0.00143	0.00155	CcSEcCtD
Lurasidone—Gastrointestinal pain—Epirubicin—liver cancer	0.00142	0.00154	CcSEcCtD
Lurasidone—Dyspepsia—Doxorubicin—liver cancer	0.00141	0.00153	CcSEcCtD
Lurasidone—Decreased appetite—Doxorubicin—liver cancer	0.00139	0.00151	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00139	0.0015	CcSEcCtD
Lurasidone—Fatigue—Doxorubicin—liver cancer	0.00138	0.0015	CcSEcCtD
Lurasidone—Abdominal pain—Epirubicin—liver cancer	0.00137	0.00149	CcSEcCtD
Lurasidone—Gastrointestinal pain—Doxorubicin—liver cancer	0.00131	0.00142	CcSEcCtD
Lurasidone—Abdominal pain—Doxorubicin—liver cancer	0.00127	0.00138	CcSEcCtD
Lurasidone—Asthenia—Epirubicin—liver cancer	0.00124	0.00135	CcSEcCtD
Lurasidone—Pruritus—Epirubicin—liver cancer	0.00123	0.00133	CcSEcCtD
Lurasidone—Diarrhoea—Epirubicin—liver cancer	0.00119	0.00129	CcSEcCtD
Lurasidone—Asthenia—Doxorubicin—liver cancer	0.00115	0.00125	CcSEcCtD
Lurasidone—Dizziness—Epirubicin—liver cancer	0.00115	0.00124	CcSEcCtD
Lurasidone—Pruritus—Doxorubicin—liver cancer	0.00114	0.00123	CcSEcCtD
Lurasidone—Vomiting—Epirubicin—liver cancer	0.0011	0.0012	CcSEcCtD
Lurasidone—Diarrhoea—Doxorubicin—liver cancer	0.0011	0.00119	CcSEcCtD
Lurasidone—Rash—Epirubicin—liver cancer	0.00109	0.00119	CcSEcCtD
Lurasidone—Dermatitis—Epirubicin—liver cancer	0.00109	0.00118	CcSEcCtD
Lurasidone—Dizziness—Doxorubicin—liver cancer	0.00106	0.00115	CcSEcCtD
Lurasidone—Nausea—Epirubicin—liver cancer	0.00103	0.00112	CcSEcCtD
Lurasidone—Vomiting—Doxorubicin—liver cancer	0.00102	0.00111	CcSEcCtD
Lurasidone—Rash—Doxorubicin—liver cancer	0.00101	0.0011	CcSEcCtD
Lurasidone—Dermatitis—Doxorubicin—liver cancer	0.00101	0.0011	CcSEcCtD
Lurasidone—Nausea—Doxorubicin—liver cancer	0.000953	0.00103	CcSEcCtD
Lurasidone—ADRA2A—Signaling Pathways—H2AFX—liver cancer	2.53e-05	0.000326	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—IL2—liver cancer	2.53e-05	0.000326	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—IL2—liver cancer	2.52e-05	0.000325	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TERT—liver cancer	2.51e-05	0.000324	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—ESR1—liver cancer	2.51e-05	0.000323	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—PIK3CB—liver cancer	2.5e-05	0.000322	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PIK3CD—liver cancer	2.49e-05	0.000321	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—F2—liver cancer	2.48e-05	0.000319	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—ALB—liver cancer	2.46e-05	0.000317	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—HRAS—liver cancer	2.46e-05	0.000316	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CG—liver cancer	2.45e-05	0.000316	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—APC—liver cancer	2.45e-05	0.000316	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CRABP1—liver cancer	2.45e-05	0.000315	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—HRAS—liver cancer	2.42e-05	0.000312	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CDKN1B—liver cancer	2.38e-05	0.000306	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CG—liver cancer	2.37e-05	0.000306	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—APC—liver cancer	2.37e-05	0.000306	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—AKT1—liver cancer	2.35e-05	0.000303	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—KDR—liver cancer	2.34e-05	0.000301	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CASP3—liver cancer	2.33e-05	0.0003	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—IL2—liver cancer	2.33e-05	0.0003	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MAPK14—liver cancer	2.32e-05	0.000299	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—IL6—liver cancer	2.32e-05	0.000298	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—BRAF—liver cancer	2.3e-05	0.000297	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CG—liver cancer	2.3e-05	0.000297	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—KDR—liver cancer	2.3e-05	0.000296	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—IL2—liver cancer	2.3e-05	0.000296	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TERT—liver cancer	2.29e-05	0.000295	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MAPK14—liver cancer	2.28e-05	0.000294	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—ESR1—liver cancer	2.28e-05	0.000293	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CCND1—liver cancer	2.27e-05	0.000292	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—JUN—liver cancer	2.26e-05	0.000292	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—F2—liver cancer	2.25e-05	0.00029	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CTNNB1—liver cancer	2.25e-05	0.000289	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—ESR1—liver cancer	2.24e-05	0.000289	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—BRAF—liver cancer	2.23e-05	0.000287	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PPARG—liver cancer	2.22e-05	0.000286	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—F2—liver cancer	2.21e-05	0.000285	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MMP9—liver cancer	2.2e-05	0.000284	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CDKN1A—liver cancer	2.2e-05	0.000283	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PIK3CB—liver cancer	2.17e-05	0.00028	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—AKT1—liver cancer	2.17e-05	0.000279	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CD—liver cancer	2.16e-05	0.000278	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CG—liver cancer	2.15e-05	0.000277	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—APC—liver cancer	2.15e-05	0.000277	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MAPK8—liver cancer	2.14e-05	0.000276	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—HPGDS—liver cancer	2.14e-05	0.000276	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—AKT1—liver cancer	2.14e-05	0.000275	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—PIK3CA—liver cancer	2.13e-05	0.000275	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—SERPINE1—liver cancer	2.13e-05	0.000275	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CG—liver cancer	2.12e-05	0.000273	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—APC—liver cancer	2.12e-05	0.000273	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—KRAS—liver cancer	2.11e-05	0.000272	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—KDR—liver cancer	2.09e-05	0.000269	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CD—liver cancer	2.09e-05	0.000269	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MAPK14—liver cancer	2.08e-05	0.000268	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—PIK3CA—liver cancer	2.07e-05	0.000266	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—SERPINE1—liver cancer	2.06e-05	0.000266	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—KRAS—liver cancer	2.04e-05	0.000263	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—ESR1—liver cancer	2.04e-05	0.000263	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CD—liver cancer	2.03e-05	0.000261	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—BRAF—liver cancer	2.02e-05	0.000261	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—F2—liver cancer	2.01e-05	0.000259	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—ALB—liver cancer	2e-05	0.000258	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—BRAF—liver cancer	1.99e-05	0.000256	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—VEGFA—liver cancer	1.98e-05	0.000255	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—STAT3—liver cancer	1.96e-05	0.000252	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—PIK3CA—liver cancer	1.94e-05	0.00025	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—APC—liver cancer	1.93e-05	0.000248	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CG—liver cancer	1.93e-05	0.000248	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—RAF1—liver cancer	1.92e-05	0.000248	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PSMD10—liver cancer	1.91e-05	0.000246	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PSMA4—liver cancer	1.91e-05	0.000246	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CD—liver cancer	1.89e-05	0.000244	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MTOR—liver cancer	1.88e-05	0.000242	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CB—liver cancer	1.88e-05	0.000242	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—PIK3CA—liver cancer	1.88e-05	0.000242	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—PIK3CA—liver cancer	1.87e-05	0.000241	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—SERPINE1—liver cancer	1.87e-05	0.000241	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CD—liver cancer	1.86e-05	0.00024	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—RAF1—liver cancer	1.86e-05	0.00024	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GOT2—liver cancer	1.86e-05	0.000239	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—KRAS—liver cancer	1.85e-05	0.000239	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—PIK3CA—liver cancer	1.84e-05	0.000238	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—SERPINE1—liver cancer	1.84e-05	0.000237	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—KRAS—liver cancer	1.82e-05	0.000235	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MYC—liver cancer	1.82e-05	0.000234	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MTOR—liver cancer	1.82e-05	0.000234	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CB—liver cancer	1.82e-05	0.000234	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TGFB1—liver cancer	1.82e-05	0.000234	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—BRAF—liver cancer	1.81e-05	0.000233	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—HRAS—liver cancer	1.79e-05	0.000231	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CB—liver cancer	1.77e-05	0.000227	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CDKN1B—liver cancer	1.76e-05	0.000227	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP2E1—liver cancer	1.74e-05	0.000225	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—AKT1—liver cancer	1.74e-05	0.000225	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—HRAS—liver cancer	1.74e-05	0.000224	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CASP3—liver cancer	1.73e-05	0.000223	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL2—liver cancer	1.73e-05	0.000222	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—IL6—liver cancer	1.72e-05	0.000221	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CDKN1B—liver cancer	1.71e-05	0.00022	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—PIK3CA—liver cancer	1.7e-05	0.000219	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CD—liver cancer	1.69e-05	0.000218	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—RAF1—liver cancer	1.69e-05	0.000218	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—AKT1—liver cancer	1.69e-05	0.000217	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—KRAS—liver cancer	1.68e-05	0.000217	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCND1—liver cancer	1.68e-05	0.000217	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—JUN—liver cancer	1.68e-05	0.000216	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—PIK3CA—liver cancer	1.68e-05	0.000216	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SERPINE1—liver cancer	1.68e-05	0.000216	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—PIK3CA—liver cancer	1.67e-05	0.000216	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CASP3—liver cancer	1.67e-05	0.000215	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL2—liver cancer	1.67e-05	0.000215	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CTNNB1—liver cancer	1.67e-05	0.000214	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—RAF1—liver cancer	1.66e-05	0.000214	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—IL6—liver cancer	1.66e-05	0.000214	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—KRAS—liver cancer	1.66e-05	0.000214	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CB—liver cancer	1.65e-05	0.000212	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MTOR—liver cancer	1.65e-05	0.000212	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MMP9—liver cancer	1.63e-05	0.00021	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYCS—liver cancer	1.63e-05	0.00021	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCND1—liver cancer	1.63e-05	0.00021	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CDKN1A—liver cancer	1.63e-05	0.00021	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—JUN—liver cancer	1.62e-05	0.000209	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MTOR—liver cancer	1.62e-05	0.000209	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CB—liver cancer	1.62e-05	0.000209	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CTNNB1—liver cancer	1.61e-05	0.000208	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GGT1—liver cancer	1.6e-05	0.000206	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GOT1—liver cancer	1.6e-05	0.000206	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MAPK8—liver cancer	1.59e-05	0.000205	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—AKT1—liver cancer	1.58e-05	0.000204	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MMP9—liver cancer	1.58e-05	0.000203	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—HRAS—liver cancer	1.57e-05	0.000203	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CDKN1A—liver cancer	1.57e-05	0.000203	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—HRAS—liver cancer	1.55e-05	0.0002	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CDKN1B—liver cancer	1.55e-05	0.000199	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—PIK3CA—liver cancer	1.55e-05	0.000199	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MAPK8—liver cancer	1.54e-05	0.000198	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—AKT1—liver cancer	1.53e-05	0.000197	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—AKT1—liver cancer	1.53e-05	0.000197	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—PIK3CA—liver cancer	1.52e-05	0.000196	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CDKN1B—liver cancer	1.52e-05	0.000196	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CASP3—liver cancer	1.52e-05	0.000195	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL2—liver cancer	1.51e-05	0.000195	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—RAF1—liver cancer	1.51e-05	0.000195	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—IL6—liver cancer	1.51e-05	0.000194	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—AKT1—liver cancer	1.51e-05	0.000194	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TP53—liver cancer	1.49e-05	0.000193	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CASP3—liver cancer	1.49e-05	0.000192	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL2—liver cancer	1.49e-05	0.000192	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—IL6—liver cancer	1.48e-05	0.000191	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCND1—liver cancer	1.48e-05	0.00019	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MTOR—liver cancer	1.48e-05	0.00019	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CB—liver cancer	1.48e-05	0.00019	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—JUN—liver cancer	1.47e-05	0.00019	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—VEGFA—liver cancer	1.47e-05	0.000189	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CTNNB1—liver cancer	1.46e-05	0.000188	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCND1—liver cancer	1.45e-05	0.000187	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—STAT3—liver cancer	1.45e-05	0.000187	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—JUN—liver cancer	1.45e-05	0.000187	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CTNNB1—liver cancer	1.44e-05	0.000185	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTP1—liver cancer	1.44e-05	0.000185	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MMP9—liver cancer	1.43e-05	0.000185	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—HRAS—liver cancer	1.43e-05	0.000184	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CDKN1A—liver cancer	1.43e-05	0.000184	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—HMOX1—liver cancer	1.42e-05	0.000183	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—VEGFA—liver cancer	1.42e-05	0.000183	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MMP9—liver cancer	1.41e-05	0.000182	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—HRAS—liver cancer	1.41e-05	0.000182	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CDKN1A—liver cancer	1.41e-05	0.000181	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—STAT3—liver cancer	1.4e-05	0.000181	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MAPK8—liver cancer	1.39e-05	0.00018	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—AKT1—liver cancer	1.39e-05	0.000179	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CDKN1B—liver cancer	1.39e-05	0.000178	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MAPK8—liver cancer	1.37e-05	0.000177	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—AKT1—liver cancer	1.37e-05	0.000177	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—IL6—liver cancer	1.37e-05	0.000176	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—AKT1—liver cancer	1.37e-05	0.000176	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CASP3—liver cancer	1.36e-05	0.000175	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL2—liver cancer	1.36e-05	0.000175	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—IL6—liver cancer	1.35e-05	0.000174	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MYC—liver cancer	1.35e-05	0.000174	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TGFB1—liver cancer	1.35e-05	0.000173	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PIK3CA—liver cancer	1.33e-05	0.000171	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTM1—liver cancer	1.32e-05	0.00017	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCND1—liver cancer	1.32e-05	0.00017	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—JUN—liver cancer	1.32e-05	0.00017	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CTNNB1—liver cancer	1.31e-05	0.000169	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MYC—liver cancer	1.31e-05	0.000168	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TGFB1—liver cancer	1.3e-05	0.000168	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—VEGFA—liver cancer	1.29e-05	0.000166	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MMP9—liver cancer	1.28e-05	0.000165	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CDKN1A—liver cancer	1.28e-05	0.000165	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—STAT3—liver cancer	1.27e-05	0.000164	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—VEGFA—liver cancer	1.27e-05	0.000163	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—AKT1—liver cancer	1.26e-05	0.000163	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—STAT3—liver cancer	1.25e-05	0.000162	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP1A1—liver cancer	1.25e-05	0.000161	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MAPK8—liver cancer	1.25e-05	0.000161	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—KRAS—liver cancer	1.25e-05	0.000161	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—AKT1—liver cancer	1.24e-05	0.00016	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—KRAS—liver cancer	1.21e-05	0.000155	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MYC—liver cancer	1.18e-05	0.000153	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TGFB1—liver cancer	1.18e-05	0.000152	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—MTHFR—liver cancer	1.17e-05	0.00015	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MYC—liver cancer	1.17e-05	0.00015	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TGFB1—liver cancer	1.16e-05	0.00015	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—VEGFA—liver cancer	1.15e-05	0.000148	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PPARA—liver cancer	1.15e-05	0.000148	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CA—liver cancer	1.15e-05	0.000147	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—STAT3—liver cancer	1.14e-05	0.000147	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CA—liver cancer	1.11e-05	0.000143	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TP53—liver cancer	1.11e-05	0.000143	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—KRAS—liver cancer	1.09e-05	0.000141	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—AKT1—liver cancer	1.08e-05	0.000139	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—KRAS—liver cancer	1.08e-05	0.000139	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CA—liver cancer	1.08e-05	0.000139	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TP53—liver cancer	1.07e-05	0.000138	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MYC—liver cancer	1.06e-05	0.000137	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—HRAS—liver cancer	1.06e-05	0.000136	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TGFB1—liver cancer	1.06e-05	0.000136	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—HRAS—liver cancer	1.03e-05	0.000132	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL6—liver cancer	1.01e-05	0.000131	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CA—liver cancer	1.01e-05	0.000129	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CA—liver cancer	9.89e-06	0.000127	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CG—liver cancer	9.82e-06	0.000126	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL6—liver cancer	9.81e-06	0.000126	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—KRAS—liver cancer	9.8e-06	0.000126	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TP53—liver cancer	9.73e-06	0.000125	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TP53—liver cancer	9.57e-06	0.000123	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PPARG—liver cancer	9.48e-06	0.000122	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—AKT1—liver cancer	9.35e-06	0.00012	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—HRAS—liver cancer	9.3e-06	0.00012	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—HRAS—liver cancer	9.15e-06	0.000118	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—AKT1—liver cancer	9.05e-06	0.000117	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CA—liver cancer	9e-06	0.000116	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL6—liver cancer	8.9e-06	0.000115	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—AKT1—liver cancer	8.79e-06	0.000113	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL6—liver cancer	8.76e-06	0.000113	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TP53—liver cancer	8.71e-06	0.000112	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CD—liver cancer	8.63e-06	0.000111	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ALB—liver cancer	8.52e-06	0.00011	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—HRAS—liver cancer	8.33e-06	0.000107	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—AKT1—liver cancer	8.21e-06	0.000106	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—AKT1—liver cancer	8.08e-06	0.000104	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL6—liver cancer	7.97e-06	0.000103	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CB—liver cancer	7.52e-06	9.69e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—AKT1—liver cancer	7.35e-06	9.47e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CA—liver cancer	4.59e-06	5.91e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—AKT1—liver cancer	3.75e-06	4.82e-05	CbGpPWpGaD
